The influence of letrozole on serum lipid concentrations in postmenopausal women with primary breast cancer who have completed 5 years of adjuvant tamoxifen (NCIC CTG MA.17L)

Wasan, Kishor M.; Goss, Paul E.; Pritchard, P H; Shepherd, Lois E.; Palmer, Michael; Liu, S.; Tu, Dongsheng; Ingle, James N.; Heath, M. F.; DeAngelis, D.; Perez, Edith A.

doi:10.1093/annonc/mdi158

Cited by 167 publications

(88 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In the MA.17 trial, hypercholesterolemia (16% versus 16%; p = .79) and cardiovascular events (5.8% for LET versus 5.6% for TAM; p = .76) occurred with a similar frequency in patients treated with LET and patients receiving placebo following 5 years of TAM therapy [22]. Recent results from the MA.17 lipid substudy also confirm that LET does not significantly alter lipid profiles in postmenopausal women with primary breast cancer who were treated with LET for 36 months in the extended adjuvant setting (samples were drawn under fasting conditions) [76].…”

Section: Ais and Cvdmentioning

confidence: 81%

Appraising Adjuvant Aromatase Inhibitor Therapy

Perez

2006

The Oncologist

View full text Add to dashboard Cite

Tamoxifen, once the gold standard adjuvant endocrine therapy for early breast cancer, is being challenged by third-generation aromatase inhibitors (AIs) that have demonstrated improved disease-free survival in a variety of adjuvant settings for early breast cancer. Tamoxifen and AIs have different safety profiles, which should allow physicians to begin to individualize treatment based on a patient's comorbidities and risk factors. Because of its properties as a partial estrogen agonist, tamoxifen has a positive effect on serum lipids and may confer a cardioprotective benefit, as well as a beneficial effect on bone health. However, tamoxifen increases the risk for endometrial cancer and cerebrovascular/thromboembolic events. In comparison, the major side effect of AIs is increased bone loss, which may heighten the risk for osteoporotic fractures and bone pain. Because of their superior efficacy and manageable side effects, AIs are a cost-effective alternative to tamoxifen, and clinical guidelines now embrace AIs as appropriate adjuvant therapy for hormone-sensitive early breast cancer. The anticipated results of ongoing trials will provide further insights into the long-term safety and application of AI therapy in the adjuvant setting.

show abstract

Section: Ais and Cvdmentioning

confidence: 81%

Appraising Adjuvant Aromatase Inhibitor Therapy

Perez

2006

The Oncologist

View full text Add to dashboard Cite

show abstract

“…Other adverse effects associated with tamoxifen use include vaginal bleeding or discharge, cataract, venous thromboembolic events, ischemic cerebrovascular events, and endometrial cancer. On the other hand, cardiac failure and other cardiovascular events, hypercholesterolemia, musculoskeletal disorders, including new-onset osteoporosis, fractures, and arthralgia are recognised adverse effects of aromatase inhibitors (18)(19)(20)(21)(22)(23)(24). DCIS is an in situ disease with an excellent 10-year survival rate of 98% (4).…”

Section: Resultsmentioning

confidence: 99%

Is Adjuvant Endocrine Therapy Indicated for DCIS Patients After Complete Surgical Excision?

Chehade

Mokbel

2018

View full text Add to dashboard Cite

show abstract

“…No significant changes in serum cholesterol, HDL cholesterol, LDL Cholesterol, triglycerides or Lp(a) occur in non-hyperlipidemic postmenopausal women treated for three years following five years of adjuvant tamoxifen [100].…”

Section: The Road To Adjuvant Treatment With Aromatase Inhibitorsmentioning

confidence: 93%

Development and evolution of therapies targeted to the estrogen receptor for the treatment and prevention of breast cancer

Jordan¹,

Brodie²

2007

Steroids

258

183

View full text Add to dashboard Cite

The enthusiasm with which the clinical community has embraced the use of antiestrogenic therapy to treat breast cancer is based upon the proven record of success that first the nonsteroidal antiestrogen tamoxifen and then the aromatase inhibitor have demonstrated in clinical trial. The reasons for the enthusiasm are obvious. Antihormonal therapy, particularly aromatase inhibition to create a "no estrogen state" in the postmenopausal breast cancer patient is effective, saves women's lives, is contributing successfully to reducing the national mortality from breast cancer, is relatively cheap and has fewer side effects and easy administration (oral) than any other anticancer strategy. However, the successful application of a therapeutic strategy to block the known growth stimulation property of estrogen in breast cancer was not greeted with such enthusiasm 40 years ago.Estrogen is essential for life. Without the critical role of estrogenic steroids, reproduction would not be possible. Based on emerging knowledge from laboratory studies, the value of modulating the steroid environment during the menstrual cycle was advanced to clinical testing during the 1950's as a means of oral contraception. The results of these studies were to change society forever.The Worcester Foundation for Experimental Biology is the place where Gregory Pincus established the scientific principles necessary to propose clinical testing of the oral contraceptive and M.C. Chang subsequently established the first protocols to perform in vitro fertilization. Simply stated, the Worcester Foundation was, at that time, the world center for steroid endocrinology and reproductive biology. Over the years, hundreds of scientists have trained at the Foundation and subsequently spread their knowledge throughout the world [1]. However, fashions in research change and new opportunities emerge.In 1971, President Nixon made a national commitment to seek a cure for cancer by signing the National Cancer Act. Mahlon Hoagland, the President of the Worcester Foundation, responded to the initiative by appointing Professor Elwood V. Jensen, Director of the Ben May Cancer Research Laboratory at the University of Chicago, to be a member of the Foundation's Scientific Advisory Board. Jensen had discovered the estrogen receptor (ER) as the putative mechanism of estrogen action in its target tissues [2]. The known link between estrogen and breast cancer suggested that "antiestrogenic strategies" might have potential as therapeutic Correspondence to: V. Craig Jordan, v.craig.jordan@fccc.edu. Present Address: Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111-2497 Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be d...

show abstract

The influence of letrozole on serum lipid concentrations in postmenopausal women with primary breast cancer who have completed 5 years of adjuvant tamoxifen (NCIC CTG MA.17L)

Cited by 167 publications

References 19 publications

Appraising Adjuvant Aromatase Inhibitor Therapy

Appraising Adjuvant Aromatase Inhibitor Therapy

Is Adjuvant Endocrine Therapy Indicated for DCIS Patients After Complete Surgical Excision?

Development and evolution of therapies targeted to the estrogen receptor for the treatment and prevention of breast cancer

Contact Info

Product

Resources

About